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ABSTRACT
Objective: To determine factors influencing overall survival following recurrence (OSFR) in 
women with low-risk endometrial cancer (EC) treated with surgery alone.
Methods: A multicenter, retrospective department database review was performed to identify 
patients with recurrent “low-risk EC” (patients having less than 50% myometrial invasion 
[MMI] with grade 1 or 2 endometrioid EC) at 10 gynecologic oncology centers in Turkey. 
Demographic, clinicopathological, and survival data were collected.
Results: We identified 67 patients who developed recurrence of their EC after initially being 
diagnosed and treated for low-risk EC. For the entire study cohort, the median time to 
recurrence (TTR) was 23 months (95% confidence interval [CI]=11.5–34.5; standard error 
[SE]=5.8) and the median OSFR was 59 months (95% CI=12.7–105.2; SE=23.5). We observed 
32 (47.8%) isolated vaginal recurrences, 6 (9%) nodal failures, 19 (28.4%) peritoneal failures, 
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and 10 (14.9%) hematogenous disseminations. Overall, 45 relapses (67.2%) were loco-
regional whereas 22 (32.8%) were extrapelvic. According to the Gynecologic Oncology Group 
(GOG) Trial-99, 7 (10.4%) out of 67 women with recurrent low-risk EC were qualified as high-
intermediate risk (HIR). The 5-year OSFR rate was significantly higher for patients with TTR 
≥36 months compared to those with TTR <36 months (74.3% compared to 33%, p=0.001). 
On multivariate analysis for OSFR, TTR <36 months (hazard ratio [HR]=8.46; 95% CI=1.65–
43.36; p=0.010) and presence of HIR criteria (HR=4.62; 95% CI=1.69–12.58; p=0.003) were 
significant predictors.
Conclusion: Low-risk EC patients recurring earlier than 36 months and those carrying HIR 
criteria seem more likely to succumb to their tumors after recurrence.
Keywords: Endometrial Neoplasms; Recurrence; Local Neoplasm Recurrence; Survival 
Analysis
INTRODUCTION
Various investigators have defined low-risk endometrial cancer (EC) as patients with disease 
confined to the uterine corpus, histologic grade 1 or 2, endometrioid histologic subtype and 
less than 50% myometrial invasion (MMI) [1-3]. Low-risk EC has a minimal risk for pelvic 
lymph node (LN) metastasis (≤5%) [3,4] and vaginal recurrence (1% to 3%) [2,5-7], with a 
high disease-free survival (DFS) rate of 95% [8]. Among patients not treated with adjuvant 
vaginal brachytherapy, the recurrence rate has been reported to range from 4% to 7% 
[2,5-7]. However, in routine practice, it appears that a subgroup of women with early-stage 
endometrioid EC are at increased risk of recurrence and death [9-11].
European Society for Medical Oncology (ESMO) Clinical Practice Guidelines has also defined 
low-risk EC as women having less than 50% MMI with grade 1 or 2 endometrioid EC [12]. 
Jeppesen et al. [13,14] have recently used the same “low-risk” terminology for management 
and follow-up strategies. According to the Surveillance, Epidemiology, and End Results 
(SEER) data, this subgroup of patients represents approximately 61% of endometrioid ECs 
grossly confined to the uterus [15,16]. Straughn et al. [17] reported this prevalence as 78% 
among women with surgically-staged stage I endometrioid EC. Although the recurrence 
rate is very low in this subgroup of patients, the absolute number of recurrences in low-risk 
EC seems to be actually considerable as approximately 70% of women with EC are given a 
diagnosis while the disease is confined to the uterus [18]. In addition, the incidence of EC is 
rapidly increasing worldwide, with the highest disease burden reported in North America and 
Western Europe [19].
Multiple factors have been identified for relative high risk of recurrence among women with 
early-stage EC such as age, depth of MMI, lymphovascular space invasion (LVSI), grade, and 
tumor size [3,11,12]. However, relapse patterns and predictive factors for survival following 
recurrence in low-risk EC have not been thoroughly delineated. Therefore, we conducted 
a retrospective multicenter study in order to involve an increased number of women with 
recurrent low-risk EC.
The purpose of this study was to determine factors influencing overall survival following 
recurrence (OSFR) in women with low-risk EC treated with surgery alone.
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MATERIALS AND METHODS
1. Study design and eligibility
Medical records of women who underwent primary surgical treatment for EC between 
January 2000 and December 2016 at 10 gynecologic oncology centers from Turkey were 
retrospectively reviewed. The study protocol was approved by the local Institutional Review 
Boards. All patients provided an informed consent regarding research use of their medical 
information.
The study population included women who developed recurrence of their endometrioid 
EC after initially being diagnosed and treated for low-risk EC. Women were included if they 
had undergone primary surgical treatment, including at least total hysterectomy with 
bilateral salpingo-oopherectomy, with or without pelvic±para-aortic lymphadenectomy. 
Since this study focused only on women having <50% MMI with grade 1 or 2 endometrioid 
EC; women with grade 3 tumors, those with ≥50% MMI were excluded as well as patients 
with non-endometrioid and mixed histologies. We also excluded patients who received 
adjuvant radiotherapy (RT), women with synchronous malignancies, and those with 
incomplete medical records.
2. Clinical information
Patient data were extracted from 10 institutions with maintained EC databases. With 
the eligible cases, the following information was abstracted from medical records: age 
at diagnosis, menopausal status, body mass index (BMI), date of diagnosis, surgical 
procedure applied, time to recurrence (TTR) (as a continuous variable or dichotomous; 
<18 months or ≥18 months, <24 months or ≥24 months, and <36 months or ≥36 months) 
[20], site of recurrence, type of salvage treatment received (surgical resection only, RT only, 
chemotherapy [CT] only, or a combination of one or more of these therapies), length of 
follow-up, and survival. Data were collected from centers with an online standardized form.
Tumor characteristics were abstracted from original pathology reports, and the following data 
were recorded: primary tumor diameter (PTD) (as a continuous variable or dichotomous; <20 
mm or ≥20 mm), presence of LVSI, lower uterine segment involvement (LUSI), and the status 
of peritoneal cytology examination (negative, positive, or not performed).
Data on the extent of surgery included status of lymphadenectomy (yes or no), pelvic 
lymphadenectomy only (yes or no), pelvic and para-aortic lymphadenectomy (yes or no), 
number of total LNs harvested (if applicable), number of pelvic LNs removed (if applicable), 
and number of para-aortic LNs removed (if applicable). All operations were performed by 
gynecologic oncologists. Lymphadenectomy was performed according to the results of 
frozen section analysis.
All surgical specimens were examined and interpreted by gynecologic pathologists. Low-
risk EC (grade 1 or 2 endometrioid EC with <50% MMI) was diagnosed after examination of 
permanent sections. Architectural grading was defined by standard International Federation 
of Gynecology and Obstetrics (FIGO) criteria. Tumor size was macroscopically measured on 
fresh tissue by gynecologic pathologists who noted size in 3 largest dimensions. The largest 
of 3 dimensions of the tumor was defined as PTD [3]. LVSI was defined as the presence of 
adenocarcinoma of any extent, in endothelium lined channels of uterine specimens extracted 
at the time of surgery [11].
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After diagnosis of recurrence, all the hematoxylin and eosin-stained slides of the primary 
tumor were reviewed by a gynecologic pathologist at each participating institution before 
initiating treatment for recurrence and the primary diagnosis of low-risk EC was confirmed. 
All tumors were staged according to the FIGO staging system [21]. In patients treated 
before 2009, stage was determined retrospectively on the basis of surgical and pathologic 
assessment. None of the patients included in the study received adjuvant hormonal 
therapy after initial diagnosis.
Postoperative cancer surveillance included follow-up visits quarterly for the first 2 years, 
and biannually thereafter. A chest radiograph and vaginal smears were obtained once a 
year. The visits included a gynecologic medical history and a gynecologic examination 
that was further supplemented with biopsies in case of suspicious findings and imaging 
studies in case of suspicion of distant metastases. If an isolated recurrence was diagnosed, 
treatment with curative intent was initiated unless precluded by the patient or disease 
factors. Salvage radiation therapy was defined as the use of any type of RT to any relapse 
site whether loco-regional or distant. After treatment for relapse, patients were again 
evaluated every 3 months for the first 2 years and every 6 months thereafter.
All women included in the study were followed until death or to the end of study period 
(31st December 2016). The survival status of the patients was determined as alive with no 
evidence of disease (NED), alive with disease (AWD), dead of intercurrent disease (DOID), 
and dead of disease (DOD) at the time of the last follow-up. For all study subjects with a 
recorded death, this was confirmed by performing a social security death index search.
3. Definitions
Within the time frame of 5 years after surgery, recurrence was defined as documentation of 
metastasis either by biopsy or imaging techniques after a DFS ≥3 months.
Site of recurrence was grouped into 4 categories: 1) vaginal relapse: recurrence within 
vaginal walls or vaginal cuff [22], 2) nodal failure: recurrence in pelvic, para-aortic node 
regions, or other node-bearing area (i.e., groin, axilla, supraclavicular, or mediastinal) as the 
primary site of failure [23], 3) peritoneal (abdominal) failure: disease recurring in the upper 
abdomen or involving the pelvic peritoneum (or both) generally manifested by ascites, 
peritonitis carcinomatosa, or intestinal obstruction [24], 4) hematogenous dissemination: 
lung, liver, or other sites (i.e., adrenals, breast, brain, bone, or skin-via hematogenous 
spread) [25]. In case of several concomitant recurrence localizations, the patient was 
involved in the group with the most advanced disease.
For statistical purposes, we also classified tumor relapses at the surgical vaginal cuff, 
vagina, pelvic sidewall, or pelvic LNs as loco-regional and all other recurrences (peritoneal, 
hematogenous, and LN recurrences outside the pelvis) as extrapelvic.
According to the Gynecologic Oncology Group (GOG) Trial-99, women in the high-
intermediate risk (HIR) group were defined as patients; 1) 50–70 years of age with grade 2 
histology and presence of LVSI, or 2) over 70 years of age with either grade 2 histology or 
presence of LVSI [11]. The primary outcome of this study was to determine independent 
predictors of OSFR in recurrent low-risk EC patients treated with surgery alone. The 
secondary outcome was to identify the recurrence rate and failure patterns in low-risk EC 
patients.
4/14https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e65
Relapse in low-risk endometrial cancer
4. Statistical analysis
Statistical analyses were performed using the statistical software package SPSS version 23.0 
(SPSS Inc., Chicago, IL, USA). The data were expressed as median and range for continuous 
variables. Binary variables were reported as counts and percentages. Categorical variables 
were evaluated using the χ2 test or Fisher's exact test as appropriate for the group size.
DFS was calculated from the date of EC diagnosis to the date of recurrence. We defined 
OSFR as the period from the diagnosis of recurrence to the patient's death or to the date 
of last follow-up. Survival curves were generated using the Kaplan-Meier method, and the 
differences between survival curves were calculated using the log-rank test. In order to 
evaluate the prognostic factors for OSFR, a Cox regression model was used. A p-value <0.05 
was considered to indicate statistical significance.
RESULTS
During the study period, a total of 8,769 endometrioid EC were treated at 10 participating 
centers. Of these women, 3,545 (40.5%) had low-risk EC (FIGO grade 1 or 2 disease with 
less than 50% MMI). We identified 78 women who developed recurrent low-risk EC. 
The prevalence of recurrent low-risk EC was 2.2%. We excluded 7 patients who received 
postoperative RT, 1 with synchronous breast cancer and 3 women with incomplete medical 
records. Therefore, the present analysis addresses the remaining 67 women with recurrent 
low-risk EC.
The median age of the patients was 58 years (range, 37–83), and their median BMI was 30.8 
kg/m2 (range, 20.6–49.1 kg/m2). Histologic grade was determined as grade 1 in 35 women 
(52.2%) whereas 32 patients had grade 2 histology (47.8%). LVSI was present in 6 women 
(9%). PTD was ≤20 mm in 25 patients (37.3%) and >20 mm in 33 (49.3%); in patients for 
whom this information was available (all but 9). LUSI was identified in 7 patients (10.4%).
Fifteen women (22.4%) were treated only with total hysterectomy and bilateral salpingo-
oopherectomy. Pelvic LN dissection only was performed in 19 patients (28.4%). However, 
pelvic and para-aortic lymphadenectomy was performed in 33 women (49.3%). The mean 
number of total LNs removed was 22.5±14.7 (range, 5–74). The mean number of pelvic and 
para-aortic LNs removed was 17.2±9.4 (range, 4–41) and 8.5±7.5 (range, 1–33), respectively. 
None of the patients in our cohort received postoperative adjuvant RT. According to the GOG 
Trial-99 [11], 7 (10.4%) out of 67 women with recurrent low-risk EC were qualified as HIR. 
All patients with HIR qualification were older than 70 years. One of them had grade 2 disease 
with LVSI whereas the remaining 6 had only grade 2 tumors. Table 1 demonstrates baseline 
characteristics of women with recurrent low-risk EC.
Median TTR was 23 months (95% confidence interval [CI]=11.5–34.5; standard error 
[SE]=5.8). The diagnosis of recurrence was biopsy proven in 36 women (53.7%) whereas 
31 patients (46.3%) had their recurrences diagnosed by only imaging studies. In our study, 
34 of recurrences (50.7%) occurred within 2 years after primary surgery whereas 44 of 
recurrences (65.7%) occurred within 3 years of initial diagnosis. We observed 32 (47.8%) 
isolated vaginal recurrences, 6 (9%) nodal failures, 19 (28.4%) peritoneal failures, and 10 
(14.9%) hematogenous disseminations. Overall, 45 relapses (67.2%) were loco-regional while 
22 (32.8%) were extrapelvic. The median TTR was not statistically significant between loco-
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regional and extrapelvic recurrences (24 months [95% CI=12.5–35.5; SE=5.8] vs. 19 months 
[95% CI=4.0–33.9; SE=7.6]; p=0.516). Site of recurrences, median TTR, and type of salvage 
therapies are summarized in Table 2.
Treatment of the recurrences was applied according to the institutional practices at that 
time, and consisted of surgical resection (n=4, 6%), radiation (n=12, 17.9%), CT (n=17, 
25.4%), surgical resection plus radiation (n=6, 9%), surgical resection plus CT (n=6, 9%), 
chemoradiaton (n=13, 19.4%), and surgical resection plus chemoradiaton (n=9, 13.4%).
The most frequent site of recurrence was the vaginal vault (47.8%) which was associated with 
a 5-year OSFR rate of 53.6%. The median OSFR has not been reached yet in women with 
isolated vaginal recurrence. Complete remission after salvage treatment for isolated vaginal 
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Table 1. Baseline characteristics of women with recurrent low-risk EC
Characteristics Values
Age (yr) 58 (37–83)
≤60 40 (59.7)
>60 27 (40.3)
BMI (kg/m2) 30.8 (20.6–49.1)
<30 26.0 (38.8)
≥30 41.0 (61.2)
Menopausal status
Premenopausal 11 (16.4)
Postmenopausal 56 (83.6)
Postoperative histologic grade
Grade 1 35 (52.2)
Grade 2 32 (47.8)
LVSI
Absent 59 (88)
Present 6 (9)
Unknown 2 (3)
Tumor size (postoperative, mm) 24.5±12.9
≤20 25 (37.3)
>20 33 (49.3)
Unknown 9 (13.4)
LUSI
Yes 7 (10.4)
No 60 (89.6)
Site of lymphadenectomy
Pelvic only 19 (28.4)
Pelvic and para-aortic 33 (49.3)
Not-performed 15 (22.4)
No. of LNs removed 22.5±14.7
No. of pelvic LNs  removed 17.2±9.5
No. of para-aortic LNs  removed 8.5±7.5
Peritoneal cytology
Positive 0 (0)
Negative 63 (94)
Not-performed 4 (6)
HIR*
Yes 7 (10.5)
No 60 (89.5)
Values are presented as median (range), number (%), or mean.
BMI, body mass index; EC, endometrial cancer; GOG, Gynecologic Oncology Group; HIR, high-intermediate risk; 
LN, lymph node; LUSI, lower uterine segment involvement; LVSI, lymphovascular space invasion.
*HIR criteria according to GOG Trial-99 [11]. Women in the HIR group were defined as patients; 1) 50–70 years 
of age with grade 2 histology and presence of LVSI, or 2) over 70 years of age with either grade 2 histology or 
presence of LVSI.
relapse was 20/32 (62.5%). The 5-year OSFR rate for nodal, peritoneal and hematogenous 
failures was 37.5%, 35.3%, and 42%, respectively. No statistically significant difference 
was observed in terms of 5-year OSFR with regard to the site of recurrence (p=0.760) (Fig. 
1). According to the site of recurrence (loco-regional vs. extrapelvic), the 5-year OSFR rate 
was 51.2% for women with loco-regional recurrences compared to 35.9% for women with 
extrapelvic recurrences (p=0.065).
Overall, for the entire study cohort, the median OSFR was 59 months (95% CI=12.7–105.2; 
SE=23.5). The 5-year OSFR rate was significantly higher for patients with TTR ≥36 months 
compared to those with TTR <36 months (74.3% vs. 33%, respectively; p=0.001). Fig. 2 shows 
the Kaplan-Meier plots for OSFR comparing those with TTR ≥36 months to TTR <36 months.
After further stratification, according to the site of recurrence (loco-regional vs. extrapelvic), 
patients with loco-regional recurrence had no difference in the 5-year OSFR rate regardless 
of when they recurred (<24 months or ≥24 months) (49.8% vs. 52.6%, respectively; p=0.640). 
However, patients with extrapelvic recurrence and TTR <24 months had a significantly worse 
5-year OSFR rate compared to those who had extrapelvic recurrences later than 24 months. For 
patients who had extrapelvic recurrences earlier than 24 months, the 5-year OSFR rate was 0% 
compared to 87.5% for those with extrapelvic recurrences and TTR ≥24 months (p=0.009).
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Table 2. Recurrence characteristics of patients
Variables Values TTR (mo)
Site of recurrence
Vaginal 32 (47.8) 24 (10.89–25.11)
Nodal 6 (9.0) 10 (3.99–16.00)
Peritoneal 19 (28.4) 18 (10.89–25.11)
Hematogenous 10 (14.9) 28 (10.95–45.04)
Loco-regional disease 45 (67.2) 24 (12.50–34.50)
Vaginal cuff 31
Vagina 1
Pelvic sidewall 13
Extrapelvic disease 22 (32.8) 19 (4.0–33.9)
Abdominal (peritoneal) disease 4
Liver-lung 2
Liver-vaginal cuff 3
Liver-para-aortic LN 1
Liver-peritoneal disease 1
Para-aortic LN 3
Bowel 1
Diaphragm 1
Mediastinal LN 1
Lung 2
Inguinal LN 1
Inguinal LN-para-aortic LN 1
Skin 1
Salvage therapies -
Surgical resection alone 4 (6.0)
RT alone 12 (17.9)
CT alone 17 (25.4)
Surgical resection plus RT 6 (9.0)
Surgical resection plus CT 6 (9.0)
Surgical resection plus CRT 9 (13.4)
CRT 13 (19.4)
Values are presented as number (%) or median (95% CI).
CI, confidence interval; CT, chemotherapy; CRT, chemoradiotherapy; LN, lymph node; RT, radiotherapy; TTR, time 
to recurrence.
We compared the OSFR rates of 7 patients in the HIR group with 60 women in the non-HIR 
group. As expected, the 5-year OSFR rate was significantly higher for patients in the non-HIR 
group compared to those with HIR criteria (55.7% compared to 0%, respectively; p=0.004). 
However, the 3-year OSFR rate for the HIR group was 17.9% while the corresponding rate was 
67.5% for the non-HIR group. Fig. 3 shows the Kaplan-Meier plots for OSFR comparing those 
with HIR criteria to the non-HIR group.
On multivariate analysis for OSFR, TTR <36 months (hazard ratio [HR]=8.46; 95% CI=1.65–
43.36; p=0.010) and presence of HIR criteria (HR=4.62; 95% CI=1.69–12.58; p=0.003) 
were significant predictors. Table 3 shows univariate and multivariate analyses of factors 
associated with OSFR in women with recurrent low-risk EC.
At the time of reporting, of the 67 patients with recurrent low-risk EC, 35 (52.2%) were alive 
with NED, 8 (11.9%) were AWD, 1 (1.5%) died of a cause not related to the disease and was 
disease free at death, and 23 (34.3%) were DOD.
8/14https://ejgo.org https://doi.org/10.3802/jgo.2017.28.e65
Relapse in low-risk endometrial cancer
p=0.760
Time (mo)
0.6
0.4
0.2
0 50 75 150
O
ve
ra
ll 
su
rv
iv
al
0.8
1.0
100 12525
Lymphatic
Hematogenous
Vaginal
Peritoneal
Lymphatic-censored
Hematogenous-censored
Vaginal-censored
Peritoneal-censored
Fig. 1. Overall survival from recurrence with regard to the site of recurrence (n=67).
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Fig. 2. Kaplan-Meier plots for OSFR comparing those with TTR ≥36 months (n=23) to TTR <36 months (n=44).
OSFR, overall survival following recurrence; TTR, time to recurrence.
DISCUSSION
Our results indicate that all types of relapse patterns (vaginal, nodal, peritoneal, and 
hematogenous) may be observed in women with low-risk EC; vaginal vault being the most 
frequent site of recurrence. Recurrent low-risk EC patients with TTR <36 months were 8 
times more likely to succumb to their tumors following recurrence whereas patients carrying 
HIR criteria were 4 times more likely to be DOD after relapse.
However, we should underline some limitations of the current study. First, the retrospective 
nature of the study cannot exclude any bias. Second, lack of central pathology review 
seems to be an important limitation. However, as mentioned before, pathology review 
was performed at each participating institution individually before initiating treatment for 
relapse. Finally, data interpretation is constrained by variation in institutional practices. 
We culled, treated, and observed patients from 10 gynecologic cancer centers; possibly 
analyzing clinical outcomes among patients with recurrence may not be equally balanced 
and objectively represented. However, given the low rate of recurrence in low-risk EC, the 
study design used here was necessary to achieve a satisfactory sample size. Despite above 
limitations, our study contributes to the limited body of knowledge associated with OSFR in 
low-risk recurrent EC.
Patients having <50% MMI with grade 1 or 2 disease represent the largest group of 
those with endometrioid EC [26]. We found the rate of low-risk EC as 40.5% among all 
endometrioid ECs at 10 gynecologic cancer centers in Turkey. Given the high rate of low-
risk EC and the rising incidence of EC worldwide, clinicians will have to deal with a large 
number of recurrent low-risk EC patients although the recurrence rate is very low in this 
clinical setting.
The recurrence rate of low-risk EC has been reported to range from 1% to 7% [3,9,11,17,27-
33]. The recurrence rate in low-risk EC was 2.2% in the current study; similar to those 
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Fig. 3. Kaplan-Meier plots for OSFR comparing those with HIR criteria (n=7) to the non-HIR group (n=60). Women 
in the HIR group were defined as patients; 1) 50–70 years of age with grade 2 histology and presence of LVSI, or 2) 
over 70 years of age with either grade 2 histology or presence of LVSI.
HIR, high-intermediate risk; LVSI, lymphovascular space invasion; OSFR, overall survival following recurrence; 
TTR, time to recurrence.
reported in the literature. However, because of the retrospective design of the current 
study, the true overall rate of recurrence in patients with low-risk EC may have been 
underestimated.
The anatomic locations of recurrences have been reported to be roughly equivalent between 
loco-regional and extrapelvic disease [11,34] with the most common sites being vaginal 
vault, pelvis, intraabdominal region, and lungs [35]. Our results implied that 67% of 
recurrences was loco-regional whereas 33% was extrapelvic. However, all types of relapse 
patterns described by Mariani et al. [22-25] were observed in our low-risk cohort. It should be 
emphasized that in only a limited number of studies in the literature, patients with low-risk 
EC have been accurately described for sites of recurrence and outcome (Table 4).
Improved survival after isolated vaginal recurrence is a well-known feature of early-stage 
EC. Complete remission after salvage treatment for isolated vaginal relapse has been 
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Table 3. Univariate and multivariate prognostic factors for overall survival from recurrence
Characteristics No. of events (%) Univariate analyses 
p-value
Multivariate analyses
HR 95% CI p-value
Age (yr) 0.216 - - -
≤60 11/40 (27.5)
>60 13/27 (48.1)
BMI (kg/m2) 0.878 - - -
<30 8/26 (30.7)
≥30 16/41 (39.0)
Histologic grade 0.320 - - -
Grade 1 9/35 (25.7)
Grade 2 15/32 (46.8)
Tumor size (mm) 0.928 - - -
≤20 9/25 (36.0)
>20 13/33 (39.4)
LVSI 0.319 - - -
Absent 20/59 (33.9)
Present 4/6 (66.6)
LUSI 0.369 - - -
Yes 1/7 (14.3)
No 23/60 (38.3)
Lymphadenectomy 0.761 - - -
Yes 20/52 (38.5)
No 4/15 (26.6)
Site of recurrence 0.065 2.320 0.988–5.486 0.053
Loco-regional 13/45 (28.8)
Extrapelvic 11/22 (50.0)
TTR (mo) 0.019 0.389 0.418–9.436 0.390
≥18 10/39 (25.6)
<18 14/28 (50.0)
TTR (mo) 0.033 0.400 0.092–2.617 0.410
≥24 8/33 (24.2)
<24 16/34 (47.0)
TTR (mo) 0.001 8.460 1.664–43.367 0.010
≥36 2/23 (8.7)
<36 22/44 (50.0)
HIR criteria 0.004 4.620 1.697–12.585 0.003
Yes 6/7 (85.7)
No 18/60 (30.0)
Women in the HIR group were defined as patients; 1) 50–70 years of age with grade 2 histology and presence of LVSI, or 2) over 70 years of age with either grade 
2 histology or presence of LVSI.
BMI, body mass index; CI, confidence interval; HIR, high-intermediate risk; HR, hazard ratio; LUSI, lower uterine segment involvement; LVSI, lymphovascular 
space invasion; TTR, time to recurrence.
reported to range from 40% to 80% in previously unirradiated patients [36]. In our study, 
the corresponding rate was 62.5% which was associated with a 5-year OSFR rate of 53.6%. 
Colombo et al. [12] reported the standard treatment for isolated vaginal recurrence as 
radiation therapy (external beam plus vaginal brachytherapy); with high rates of local 
control, complete response, and a 5-year survival rate of 50%. However, we were unable 
to demonstrate a significant difference in terms of 5-year OSFR with regard to the site of 
recurrence. The 5-year OSFR rate was 51.2% for women with loco-regional recurrences 
compared to 35.9% for women with extrapelvic recurrences (p=0.065). According to our 
findings, it does not seem reasonable to recommend a distinction between loco-regional and 
extrapelvic recurrences while evaluating the prognosis following recurrence in low-risk EC.
Various factors have been suggested to be prognostic for OSFR in recurrent EC including 
site of recurrence (loco-regional or distant), endometrioid histology, use of adjuvant 
radiation therapy, initial tumor grade, age at the time of recurrence, and TTR [12,20,37]. 
However, predictive factors for OSFR in recurrent low-risk EC have not been specifically 
reported to date. Presence of HIR criteria and TTR <36 months were found to be 
independent risk factors for decreased OSFR in low-risk EC in the current study. It should 
be kept in mind that low-risk EC patients may be qualified as HIR with the contribution 
of age (>70 years), histologic grade (grade 2), and presence of LVSI. Our data showed that 
patients with HIR criteria had a statistically significant OSFR disadvantage when compared 
to women in the non-HIR group.
Robbins et al. [20] reported that the prognostic impact of TTR was less important than the 
site of recurrence in a series of 57 women with recurrent early-stage endometrioid EC. The 
authors suggested the uniform endometrioid histology and the fairly high success rate of 
salvage therapy as probable reasons why TTR was not statistically significant in their cohort 
[20]. However, TTR <36 months appeared as an independent risk factor for decreased OSFR 
in our low-risk study population. This may be due to the difference between the study 
populations (recurrent early-stage endometrioid EC vs. recurrent low-risk EC) as well as 
different institutional practices for salvage therapies.
Because this study was limited only to patients having less than 50% MMI with grade 1 or 
2 histology, it is not surprising that some of the prognostic factors such as grade, LVSI and 
LUSI were not significant predictors of OSFR. However, to the best our knowledge, this 
study reports on the largest series of recurrent low-risk EC patients and is the first study 
evaluating OSFR specifically in those patients. The strengths of the current study lie in its 
multicenter nature with a large number of patients with recurrent low-risk EC, and the 
uniformity of applying no adjuvant treatment.
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Table 4. The absolute number of recurrences, site of recurrence, and outcome of patients with recurrent low-risk EC reported in the English literature
Studies Total recurrences reported Loco-regional recurrence DOD Extrapelvic recurrence DOD
Orr et al. [28] 4 0 0 4 3
Mariani et al. [3] 10 6 0 4 2
Alektiar et al. [29] 10 5 1 5 2
Straughn et al. [17] 11 7 0 4 4
O'Brien et al. [30] 3 2 2 1 1
dos Reis et al. [31] 2 2 2 0 0
Lee et al. [32] 7 5 1 2 2
Total 47 27 6 20 14
Present study 67 45 12 22 11
DOD, dead of disease; EC, endometrial cancer.
Since low-risk EC generally shows an excellent prognosis, its potential risk of lethal 
outcome is frequently underestimated. However, 34% of women with recurrent low-risk EC 
were DOD in the present study. It can be speculated that among women with low-risk EC, 
there seems to be subsets of patients with unknown additional negative prognostic factors 
leading them into a dead end.
According to our results, TTR <36 months and presence of HIR criteria seem to be 
independent predictors of decreased OSFR in low-risk EC patients. We conclude that 
clinicians should be cautious about the possibility of presence of HIR criteria among 
women with low-risk EC. Low-risk EC patients carrying HIR criteria should receive adjuvant 
treatment rather than surgery alone.
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